Provectus Biopharmaceuticals, Inc. (PVCT)

Market Cap	81.39M
Revenue (ttm)	557,710
Net Income (ttm)	-3.15M
Shares Out	419.52M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,734
Open	0.195
Previous Close	0.195
Day's Range	0.181 - 0.195
52-Week Range	0.056 - 0.225
Beta	0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 22, 2023

About PVCT

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adul...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: PVCT

Financial Performance

In 2023, PVCT's revenue was $557,710, a decrease of -43.61% compared to the previous year's $989,042. Losses were -$3.10 million, -12.73% less than in 2022.